104 of the 173 patients for whom histological data were available) 18 patients (17%) would have received unnecessary treatment.
patients: the 30 year report. Cancer 1974; 30:1145-50. (Accepted 263July 1984) SHORT REPORTS Immobilisation hypercalcaemia in adults and treatment with clodronate Hypercalcaemia is a recognised complication of prolonged immobilisation. It occurs in patients with high rates of bone turnover, including children and adolescents,1 and is thought to be due to an increase in net bone resorption.2 In adults severe immobilisation hypercalcaemia is rare, but milder degrees may be more common than hitherto recognised.3 We report two cases. concentration was raised at 3-92 mmol/I (15-7 mg/100 ml), fell transiently after treatment with intravenous saline, but rose again to 3-66 mmol/l (14-6 mg/100 ml) despite continuous rehydration for 19 days.
Case 2-A 32 year old woman underwent renal transplantation three months before presentation. Radiographs and serum alkaline phosphatase activity showed no evidence of bone disease, but 14 months previously she had received lax-hydroxycholecalciferol for hyperparathyroid bone disease. Renal function was stable (creatinine clearance 38 ml/min), and immunosuppression was maintained with azathioprine and prednisolone. One month after transplantation she developed cough and dyspnoea, subsequently attributed to cytomegalovirus infection, and required assisted ventilation for four weeks. She then developed a generalised grade II limb weakness due to a peripheral motor neuropathy. Power returned gradually over the subsequent two months, but serum calcium concentration rose to 3-54 mmol/l (14 mg/100 ml) despite adequate hydration and treatment with prednisolone (10 mg daily).
In both patients serum immunoreactive parathyroid hormone was undetectable (<40 pg/ml) and the concentration of 1,25-dihydroxycholecalciferol was low (21 pmol/l (8-2 pg/ml) and 42 pmol/l (16-9 pg/ml) respectively; normal pmol/l (18-55 pg/ml)). Both patients had biochemical evidence of increased bone resorption as judged by high ratios of fasting urinary calcium to creatinine concentrations (figure) and of hydroxyproline to creatinine concentrations (374 and 83-3 mmol/mol (434 and 97 mg/g) respectively (normal 10-30 mmol/mol (12-35 mg/g)). Both patients were treated with clodronate and became normocalcaemic within five days (figure). When treatment was stopped after five days in case 2 the hypercalcaemia recurred, but it responded to further treatment. Fasting urinary calcium excretion, initially high in both patients, fell to normal within two weeks after the start of treatment. In case 1 both serum calcium concentration and fasting urinary calcium excretion rose transiently when clodronate was stopped after one month of treatment. Urinary hydroxyproline excretion was initially unchanged but fell gradually to normal after three months in both patients.
Comment
It is not clear whether the increasing mobility of our two patients may in some way have triggered their hypercalcaemia. Serum concentrations of 1,25-dihydroxycholecalciferol were low, suggesting that intestinal absorption of calcium was also low. The undetectable concentrations of immunoreactive parathyroid hormone excluded hyperparathyroidism as a cause for the hypercalcaemia.
Both patients had biochemical evidence of increased bone resorption, and in both creatinine clearance was impaired. Impairment of renal function would not cause, but is likely to contribute to, hypercalcaemia, and in both cases appreciable bone resorption appeared to be the major mechanism for hypercalcaemia. These conclusions are supported by the response of these patients to clodronate. This agent has been previously used in Paget's disease and hypercalcaemic disorders associated with increased bone resorption.4 The effects of clodronate in immobilisation hypercalcaemia have not been reported previously, although the drug inhibits bone loss after immobilisation in experimental animals and in paraplegia. Plasma calcium concentration and fasting urinary calcium excretion decreased in both our patients, indicating the efficacy of treatment. The diphosphonate etidronate is also effective,5 but its action to impair mineralisation may limit the hypocalcaemic effect. The ease with which diphosphonates may be used and the absence of appreciable side effects4 make this an attractive treatment not only for immobilisation hypercalcaemia but also for the more commonly observed hypercalciuria and bone loss.
We thank Gentili for the clodronate used in these patients. 
Hyperviscosity syndrome in IgE myeloma
Only 11 cases of IgE myeloma were reported during 1967-81.1 The disease differs from classic myeloma in that patients affected are younger and predominantly male. Anaemia is severe (several patients have either presented with or developed plasma cell leukaemia), and overall survival is short (<24 months). Hypercalcaemia, renal failure, osteolytic lesions, and osteosclerosis2 3 are rare. We report on a patient with a classic hyperviscosity syndrome, a previously unrecognised complication of IgE myeloma.4
Case report A 66 year old woman was diagnosed as having a light chain myeloma in December 1980, when her serum IgG, IgA, and IgM concentrations were all low, Bence-Jones protein was present in serum and urine, and cryoglobulin was noted in the serum. The diagnosis was confirmed by a bone marrow biopsy showing >50% plasma cells. Skeletal survey and renal function were normal. Cyclophosphamide 50 mg twice daily and prednisolone 20 mg daily were given, and she progressed satisfactorily.
In April 1982 she developed generalised weakness and became semicomatose. The hyperviscosity syndrome was diagnosed as she had the classic fundal haemorrhagic changes of hyperviscosity (figure). Plasma viscosity could not be measured accurately because of the presence of a cryoglobulin, which was found to consist of IgEx monoclonal protein.
Gross antigen excess made measurement by radioimmunoassay difficult, but densitometry gave a serum IgE paraprotein concentration of 3 g/l. Other serum concentrations were: total protein 64 g/l, IgG 3 0 g/l (normal 9-16 g/l), IgA 0-6 g/l (normal 0-9-4 5 g/l), and IgM 0-2 g/l (normal 0-65-2-0 g/l). Haemoglobin concentration was 10-9 g/dl; white cell count 6-3 X 109/1 (77% neutrophils, 15% lymphocytes, 5% monocytes, 3% esinophils, and no plasma cells); and platelet count 329x l09/l. The marrow had 50% plasma cells, which contained IgEx, and the remaining marrow elements were remarkably well preserved.
She immediately underwent plasmapheresis, receiving two exchanges of three litres at a 12 hour interval. The replacement fluid, which was purified protein fraction, was returned using a warming coil, thus avoiding flow problems. Rapid clinical improvement followed and, although the reduction in serum paraprotein concentration was not assessed, the measured titre of cryoglobulin fell dramatically.
Subsequent treatment was with CHOP (cyclophosphamide 750 mg/M2, doxorubicin 30 mg/M2, and vincristine 2 mg all intravenously on day 1, and prednisolone 40 mg daily by mouth for five days) for four courses at six-weekly intervals. This produced a good partial response, reducing plasma cells in the marrow to below 10%, and treatment was stopped.
Her clinical condition began to deteriorate in January 1983, when further treatment with CHOP was ineffective. She died of marrow failure associated with infection 27 months after presentation. Necropsy was not performed.
Retinal photograph showing papilloedema and haemorrhage associated with hyperviscosity caused by IgE paraprotein acting as a cryoglobulin.
Comment
The hyperviscosity syndrome occurred when the serum IgE concentration was 3 g/l and was caused by the physical property of the protein acting as a cryoglobulin. On relapse the concentration was 2 g/l, but this was not associated with clinical hyperviscosity. Further biochemical analysis of the protein showed that the molecular size and molecular weight of the heavy chain were consistent with those of IgE. Results of further enzymatic dissection of the protein are awaited. The initial response to plasmapheresis and lack of technical problems were gratifying, and we recommend this treatment for cryoglobulinaemia with hyperviscosity.
The CHOP chemotherapy regimen was used because previous treatment with an alkylating agent and steroids at low dose had ceased to be effective. We were pleasantly surprised by the response to treatment, and are uncertain whether prolonged chemotherapy may have caused additional improvement. The fundal appearances returned to normal six weeks after plasmapheresis. Of the 11 patients studied by Endo et al,1 only two survived for longer than 24 months, but details of their treatment were not discussed. We consider plasmapheresis and the CHOP regimen to be valuable alternative treatment for this unusual form of myeloma.
We thank Professor Roger Pain for analysing the molecular size of the paraprotein.
